A significant milestone for Dalgety and the UK Medical Cannabis Industry
I am immensely proud to share a significant milestone with you today – the launch of Dalgety’s first medical cannabis product!
This milestone represents a significant advancement for our company, and more importantly, for patients and the medical cannabis industry as a whole. By establishing a UK-based medical cannabis operation, we can significantly reduce the length and time the product takes to move through the supply chain and deliver a higher quality medication to cannabis clinics and patients.
Dalgety’s mission has always been to raise the standards in the UK medical cannabis industry, this is for the ultimate benefit of the patient and it will force other cultivators, producers and CBMPs manufacturers to raise their game too!
Dalgety is determined to elevate patient care through consistent supply of high-quality, GMP-certified medical cannabis and I want to make these promises to you now:
- We have an unrelenting ‘patient first’ approach to all decisions we make
- We will never cut corners
- We will take an open and honest approach, when conveying any information or company updates to you.
Our persistent pursuit of the highest quality has one key issue. An issue we are taking very seriously. Dalgety will not be able to produce the cheapest product available on the market. The race to the bottom for price, is not a race we can be a part of. It involves cutting corners and ultimately missing key steps that impact quality of the product. We know we need to be affordable and to give all patients access to our medication and we are continuously working with our partners to make this happen.
Our team’s expertise and dedication to consistently produce pharmaceutical-grade cannabis and meet the highest standards of quality and safety, is the foundation of the company. It provides reliability and builds trust with prescribers and patients.
Looking ahead, Dalgety is poised for significant growth.
We plan to expand our cultivation output by 5.5 times over the next 18 months, which will enable us to offer a wider range of products. Additionally, based on feedback from medical cannabis clinicians and industry partners, we are investing in new extraction capabilities at our facility to be able to launch new product formats that can be prescribed to more diverse patient groups.
Collaboration remains a key element of our approach, and we welcome partnerships with new entrants in the medical cannabis industry. Dalgety will also begin international collaborations, by becoming a UK base for international cannabis companies looking to access the UK market. These new collaborations will speed up our ability to give a wider range of products and distribute a greater volume of products throughout the UK.
I am also pleased to introduce Dalgety’s new website, designed to serve as a comprehensive resource for industry partners, prescribers, and the broader medical community. The website offers educational materials on medical cannabis and detailed information about practices and processes. Greater transparency leads to greater knowledge. Greater knowledge gives more empowerment to doctors and patients when prescribing cannabis-based medicines.
We invite doctors and industry partners to explore our new website and discover more about Dalgety’s products and the benefits of medical cannabis. Your feedback and collaboration are essential as we continually strive to improve the patient experience.
Our collective efforts are raising the standard of care in the medical cannabis industry. We look forward to building on this foundation and achieving even greater success together.
Best regards,
James Leavesley
Chief Executive, Dalgety
